ATE323684T1 - Verfahren und zusammensetzungen unter verwendung von chinazolinonen - Google Patents

Verfahren und zusammensetzungen unter verwendung von chinazolinonen

Info

Publication number
ATE323684T1
ATE323684T1 AT01932769T AT01932769T ATE323684T1 AT E323684 T1 ATE323684 T1 AT E323684T1 AT 01932769 T AT01932769 T AT 01932769T AT 01932769 T AT01932769 T AT 01932769T AT E323684 T1 ATE323684 T1 AT E323684T1
Authority
AT
Austria
Prior art keywords
quinazolinones
compositions
methods
associatged
formulae
Prior art date
Application number
AT01932769T
Other languages
English (en)
Inventor
Jeffrey T Finer
Gustav Bergnes
Bainian Feng
Whitney W Smith
John C Chabala
David J Morgans Jr
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Application granted granted Critical
Publication of ATE323684T1 publication Critical patent/ATE323684T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fats And Perfumes (AREA)
AT01932769T 2000-06-21 2001-04-27 Verfahren und zusammensetzungen unter verwendung von chinazolinonen ATE323684T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21310400P 2000-06-21 2000-06-21
US09/699,047 US6545004B1 (en) 1999-10-27 2000-10-24 Methods and compositions utilizing quinazolinones

Publications (1)

Publication Number Publication Date
ATE323684T1 true ATE323684T1 (de) 2006-05-15

Family

ID=26907773

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01932769T ATE323684T1 (de) 2000-06-21 2001-04-27 Verfahren und zusammensetzungen unter verwendung von chinazolinonen

Country Status (23)

Country Link
US (7) US6545004B1 (de)
EP (2) EP1296959B1 (de)
JP (1) JP4854906B2 (de)
KR (1) KR100847788B1 (de)
CN (1) CN1229353C (de)
AT (1) ATE323684T1 (de)
AU (3) AU5927001A (de)
BR (1) BR0111898A (de)
CA (1) CA2413426C (de)
CY (1) CY1105070T1 (de)
CZ (1) CZ303007B6 (de)
DE (1) DE60118921T2 (de)
DK (1) DK1296959T3 (de)
ES (1) ES2262649T3 (de)
HU (1) HU229078B1 (de)
IL (1) IL153554A (de)
MX (1) MXPA02012627A (de)
NO (1) NO324440B1 (de)
NZ (1) NZ523233A (de)
PL (1) PL204525B1 (de)
PT (1) PT1296959E (de)
SI (1) SI1296959T1 (de)
WO (1) WO2001098278A1 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965825A (en) 1981-11-03 1990-10-23 The Personalized Mass Media Corporation Signal processing apparatus and methods
US7831204B1 (en) 1981-11-03 2010-11-09 Personalized Media Communications, Llc Signal processing apparatus and methods
JP4831906B2 (ja) 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
US20070021493A1 (en) * 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ES2263501T3 (es) * 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
NZ526622A (en) * 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
WO2003000292A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
CA2459583A1 (en) * 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
US7053216B2 (en) * 2001-11-19 2006-05-30 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
DK1847534T3 (da) * 2001-12-11 2011-08-29 Kyowa Hakko Kirin Co Ltd Thiadiazolin-derivater til behandling af kræft
AU2003213092A1 (en) * 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
EP1521746B1 (de) * 2002-03-07 2011-04-27 X-Ceptor Therapeutics, Inc. Chinazolinon modulatoren von nukleinrezeptoren
DE60333094D1 (de) * 2002-04-17 2010-08-05 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1503993A4 (de) * 2002-05-09 2006-05-03 Cytokinetics Inc Verbindungen, verfahren und zusammensetzungen
JP2005530785A (ja) * 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1513820A4 (de) * 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1556357A4 (de) * 2002-06-14 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1539727B1 (de) * 2002-07-17 2009-02-18 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
US7211580B2 (en) * 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) * 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2006501306A (ja) * 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
SE0300627D0 (sv) * 2003-03-07 2003-03-07 Astrazeneca Ab Novel fused heterocycles and uses therof
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
JP2006523232A (ja) * 2003-04-10 2006-10-12 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
ATE537158T1 (de) 2003-04-18 2011-12-15 Kyowa Hakko Kirin Co Ltd M-stage-kinesin-inhibitor
EP1620092A4 (de) * 2003-05-07 2008-04-16 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1622878A4 (de) * 2003-05-15 2008-04-09 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
AU2004247551A1 (en) * 2003-06-10 2004-12-23 Fuji Photo Film Co., Ltd. Thiadiazoline derivative
EP1636225B1 (de) * 2003-06-20 2010-02-24 Novartis Vaccines and Diagnostics, Inc. Pyridino¬1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs
CN1835746A (zh) * 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
EP1670456A2 (de) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
EP1671957A4 (de) * 2003-10-10 2007-03-14 Thiadiazolinderivate
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
WO2005051922A1 (en) * 2003-11-25 2005-06-09 Chiron Corporation Quinazolinone compounds as anticancer agents
JP2007513154A (ja) 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
WO2005061518A1 (en) * 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2007517071A (ja) * 2003-12-19 2007-06-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
EP1697331A4 (de) * 2003-12-19 2010-08-04 Merck Sharp & Dohme Inhibitoren von mitotischem kinesin
WO2005095360A1 (en) 2004-04-02 2005-10-13 Prana Biotechnology Limited Neurologically-active compounds
US7504413B2 (en) * 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7795448B2 (en) * 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
JP2008502721A (ja) * 2004-05-21 2008-01-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 分裂キネシンインヒビターとしての置換キノリン誘導体
US20050282834A1 (en) * 2004-06-09 2005-12-22 Fady Malik Compositions, devices and methods for treating cardiovascular disease
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
BRPI0513513A (pt) * 2004-07-22 2008-05-06 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
BRPI0514390A (pt) * 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
WO2006026597A2 (en) * 2004-08-30 2006-03-09 Smithkline Beecham Corporation Novel compositions and methods of treatment
CA2584412C (en) * 2004-09-14 2017-05-09 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
EP1807399A2 (de) * 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indol- und benzimidazolderivate
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
US20070161644A1 (en) * 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
NZ560320A (en) * 2005-01-25 2011-02-25 Prolexys Pharmaceuticals Inc Quinoxaline derivatives as antitumor agents
AU2006225637A1 (en) * 2005-03-22 2006-09-28 Fuji Photo Film Co., Ltd. Therapeutic agent for hematopoietic tumor
JP5060285B2 (ja) * 2005-03-22 2012-10-31 協和発酵キリン株式会社 固形腫瘍治療剤
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
WO2006137490A1 (ja) * 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
EP1940407B1 (de) * 2005-09-26 2010-11-10 Merck Sharp & Dohme Corp. N-(4-oxo-3,4-dihydrochinazolin-2-yl)butanamide als androgenrezeptormodulatoren
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
WO2007149476A2 (en) * 2006-06-19 2007-12-27 Trustees Of Columbia University In The City Of New York Assays for non-apoptotic cell death and uses thereof
EP2044222A4 (de) * 2006-07-27 2010-03-03 Hspa1a als marker für sensitivität gegen ksp-hemmer
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
JP2010515687A (ja) * 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
CN101801937A (zh) * 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
WO2009002553A1 (en) * 2007-06-25 2008-12-31 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009141541A2 (fr) 2008-04-22 2009-11-26 Centre National De La Recherche Scientifique Nouvelles compositions inhibant la melanogenese et leurs utilisations
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US8927559B2 (en) * 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2455456A1 (de) 2010-11-22 2012-05-23 Institut Curie Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
EP2699567A1 (de) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
AU2013364070B2 (en) 2012-12-21 2016-10-27 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
TW201441216A (zh) 2012-12-21 2014-11-01 Gilead Calistoga Llc 肌醇磷酯３－激酶的抑制劑
TR201806822T4 (tr) 2013-06-14 2018-06-21 Gilead Calistoga Llc Fosfatidilinositol 3-kinaz inhibitörleri.
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2023203254A2 (en) * 2022-04-22 2023-10-26 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity
WO2024223617A1 (en) * 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1249281B (de) 1963-05-18
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
US3846549A (en) 1966-09-03 1974-11-05 Boehringer Sohn Ingelheim Pharmaceutical compositions containing an n-(1-bicyclic aryl-propyl -2)-n-phenyl-piperazine
BG16042A3 (bg) 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3962244A (en) 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
EP0009008A3 (de) 1978-09-08 1980-05-14 Ciba-Geigy Ag Cephalosporinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US4281127A (en) 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
DE3177130D1 (de) 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
EP0090068A1 (de) 1982-03-31 1983-10-05 Hans Wenner Münzautomat für Zeitungen, Zeitschriften, Lebensmittel oder andere Waren
GB8524663D0 (en) 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0625123B2 (ja) 1985-12-12 1994-04-06 大塚製薬株式会社 カルボスチリル誘導体−シクロデキストリン包接化合物
JPH0333118Y2 (de) 1986-02-20 1991-07-12
DE3609598A1 (de) 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4670560A (en) * 1986-04-28 1987-06-02 Ortho Pharmaceutical Corporation Thienopyrimidine-2,4-dione derivatives and intermediates thereof
US4729996A (en) 1986-05-29 1988-03-08 Harbor Branch Oceanographic Institution, Inc. Antitumor compositions and their methods of use
DE3721855A1 (de) 1987-03-12 1988-09-22 Merck Patent Gmbh Aminosaeurederivate
GB8707053D0 (en) 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4808590A (en) 1987-07-17 1989-02-28 Harbor Branch Oceanographic Institution, Inc. Antiviral, antitumor and antifungal compositions and their methods of use
US4866084A (en) 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
JPS6430768A (en) * 1987-07-28 1989-02-01 Toshiba Corp Thermal head
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4857530A (en) 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
EP0341990B1 (de) 1988-05-10 1994-11-09 Imperial Chemical Industries Plc Cephalosporine, Verfahren zu ihrer Herstellung und pharmazeutische Präparate
GB8820129D0 (en) 1988-08-24 1988-09-28 Schering Agrochemicals Ltd Fungicides
GB8827820D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US4970226A (en) 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
JPH05504969A (ja) 1990-02-13 1993-07-29 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル要素を含有するアンギオテンシン２アンタゴニスト類
IL98167A0 (en) 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0481614A1 (de) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituierte Pyridopyrimidinone und verwandte Heterocyclen als Angiotensin-II-Antagoniste
US5411431A (en) * 1991-01-09 1995-05-02 Crown Gear, B.V. Method for crown gear grinding by generation
GB9105771D0 (en) 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
CA2079982A1 (en) 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
ATE266033T1 (de) 1992-03-12 2004-05-15 Smithkline Beecham Plc N- (1-nbutyl-4-piperidyl)methyl -3,4-dihydro-2h- 1,3 oxazino 3,2-a indol-10-carboxamid oder ein pharmazeutisch annehmbares salz davon
GB9205907D0 (en) 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
WO1993023404A1 (en) 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
JPH06148835A (ja) 1992-11-04 1994-05-27 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその処理方法
US5817662A (en) 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
WO1994015605A1 (en) 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994016704A1 (en) 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5574057A (en) 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5401745A (en) 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5837703A (en) 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5342944A (en) 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US20020198326A1 (en) 1993-11-12 2002-12-26 Taizo Aoyama Polyolefin resin composition
US5589489A (en) 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CA2113229C (en) 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
WO1995019171A1 (en) 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
AU1967495A (en) 1994-02-18 1995-09-04 Cell Therapeutics, Inc. Intracellular signalling mediators
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
JPH09165385A (ja) * 1994-08-26 1997-06-24 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US5891879A (en) 1994-08-31 1999-04-06 Hadasit Medical Research Services & Development Co., Inc. Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
HUP9801828A3 (en) 1995-03-14 2001-02-28 Novartis Ag Benzoic acid, quinoline and quinazoline derivatives, pharmaceutical compositions containing them and process for producing them
US5908930A (en) 1995-03-15 1999-06-01 Pfizer Inc. 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US5753664A (en) 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
DE69600978T2 (de) * 1995-03-28 1999-04-15 Tanabe Seiyaku Co., Ltd., Osaka Verfahren zur Herstellung von D-Aminosäuren
WO1996039403A1 (en) 1995-06-05 1996-12-12 Neurogen Corporation 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles as dopamine receptor ligands
US6245768B1 (en) 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CN1090621C (zh) 1995-08-30 2002-09-11 株式会社大冢制药厂 制备喹唑啉－4－酮衍生物的方法
WO1997010221A1 (en) 1995-09-15 1997-03-20 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
DE19546918A1 (de) 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
PT901487E (pt) 1996-05-15 2003-08-29 Pfizer 4(3h)-quinazolinonas 2,3,6-trissubstituidas
US6008010A (en) 1996-11-01 1999-12-28 University Of Pittsburgh Method and apparatus for holding cells
AU5380398A (en) * 1996-12-17 1998-07-15 E.I. Du Pont De Nemours And Company Fungicidal quinazolinones
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
ATE303997T1 (de) 1997-06-09 2005-09-15 Pfizer Prod Inc Chinazolin-4-on ampa antagonisten
JP3514774B2 (ja) 1997-06-25 2004-03-31 ファイザー・インク 成長ホルモン分泌促進薬としてのジペプチド誘導体
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
EP0903344B1 (de) 1997-08-21 2011-01-26 Shiseido Co., Ltd. Chinazolin-4-on Derivate, deren Herstellung und deren Verwendung als Haarwuchsmittel oder in äusserlich anzuwendenden Hautpflegemitteln
JP2934628B2 (ja) * 1997-08-21 1999-08-16 株式会社資生堂 キナゾリノン誘導体及び養毛剤、皮膚外用剤
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
AU2107199A (en) * 1998-01-08 1999-07-26 Regents Of The University Of California, The Kinesin motor modulators derived from the marine sponge (adocia)
US6214879B1 (en) * 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2000000491A1 (en) 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
AU5322399A (en) 1998-07-27 2000-02-21 President And Fellows Of Harvard College Method of high-throughput screening of molecules and compounds for their effectson biological and chemical processes
US6596497B1 (en) * 1999-03-17 2003-07-22 New York Blood Center, Inc. Screening of antiviral compounds targeted to the HIV-1 gp41 core structure
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
US6197488B1 (en) 1999-07-21 2001-03-06 Eastman Kodak Company Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity
JP4831906B2 (ja) * 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
US6156758A (en) 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
ATE286033T1 (de) 1999-09-16 2005-01-15 Curis Inc Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
CA2385921A1 (en) 1999-09-28 2001-04-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Quinazolinones
BR0014311A (pt) 1999-09-28 2002-05-21 Merck Patent Gmbh Quinazolinonas
AU7734700A (en) 1999-10-01 2001-05-10 Advanced Medicine, Inc. Macrocyclic quinazolinones and their use as local anesthetics
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6476041B1 (en) * 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6495561B2 (en) * 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
JP2003520355A (ja) 2000-01-13 2003-07-02 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 原ソースから離れた後の圧縮コンテンツ保護
ES2159488B1 (es) 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.
WO2001070737A2 (en) 2000-03-20 2001-09-27 Sepracor, Inc. Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2001074344A2 (en) 2000-03-30 2001-10-11 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
DK2223922T3 (en) 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
US6689381B2 (en) 2000-06-09 2004-02-10 Osi Pharmaceuticals, Inc. Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1174430A1 (de) 2000-07-20 2002-01-23 Universität Konstanz Verfahren zur Herstellung von Heteroringen unter Verwendung von C1-Bausteinen
NZ523749A (en) 2000-07-26 2005-03-24 Smithkline Beecham P Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
WO2002009713A2 (de) 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
MXPA03001306A (es) 2000-08-11 2003-10-15 Boehringer Ingelheim Pharma Compuestos heterociclicos utiles como inhibidores de las quinasas de tirosina.
US20020165221A1 (en) 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU9684401A (en) 2000-10-13 2002-04-22 Curis Inc Hedgehog antagonists, methods and uses related thereto
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
US7081460B2 (en) * 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US20030096813A1 (en) * 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
US7365199B2 (en) * 2001-04-20 2008-04-29 Fujifilm Corporation Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
EP1396488A1 (de) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Kondensierte heterocyclische verbindung und deren medizinische verwendung
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US6936842B2 (en) * 2001-06-27 2005-08-30 Applied Materials, Inc. Method and apparatus for process monitoring
US6596723B1 (en) * 2001-07-16 2003-07-22 Essential Therapeutics, Inc. Fungal efflux pump inhibitors
US20030220338A1 (en) * 2001-07-16 2003-11-27 Watkins Will J. Fungal efflux pump inhibitors
AU2002322585A1 (en) * 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
CA2459583A1 (en) 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
JP2005501887A (ja) * 2001-09-05 2005-01-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 癌の処置における組成物およびその使用
DE60209381T2 (de) 2001-10-26 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
SI1441734T1 (sl) 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
US7053216B2 (en) * 2001-11-19 2006-05-30 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2003049679A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2443023A1 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1521746B1 (de) 2002-03-07 2011-04-27 X-Ceptor Therapeutics, Inc. Chinazolinon modulatoren von nukleinrezeptoren
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US6900219B2 (en) * 2002-04-04 2005-05-31 Cv Therapeutics, Inc. ABCA-1 elevating compounds
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1503993A4 (de) 2002-05-09 2006-05-03 Cytokinetics Inc Verbindungen, verfahren und zusammensetzungen
EP1513820A4 (de) 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1515949B1 (de) 2002-06-14 2007-03-14 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
EP1556357A4 (de) 2002-06-14 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
KR20050010515A (ko) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
EP1551962A4 (de) 2002-07-08 2007-08-01 Merck & Co Inc Mitotische kinesin-bindungsstelle
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
JP2006500327A (ja) 2002-07-10 2006-01-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 精子の運動性を増大させるための化合物の使用
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
AU2003263323A1 (en) 2002-09-07 2004-03-29 Celltech R And D Limited Quinazolinone derivatives
JP2006501306A (ja) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
ATE488231T1 (de) 2002-12-23 2010-12-15 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
JP2006515886A (ja) 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
JP3947758B2 (ja) 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
EP1663237B1 (de) * 2003-09-10 2013-06-19 Icagen, Inc. Kondensierte ringheterozyklen als kaliumkanalmodulatoren
WO2005051922A1 (en) * 2003-11-25 2005-06-09 Chiron Corporation Quinazolinone compounds as anticancer agents
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050282834A1 (en) * 2004-06-09 2005-12-22 Fady Malik Compositions, devices and methods for treating cardiovascular disease

Also Published As

Publication number Publication date
US20040023996A1 (en) 2004-02-05
DE60118921D1 (de) 2006-05-24
US6545004B1 (en) 2003-04-08
CZ20024178A3 (cs) 2003-05-14
AU2006236024A1 (en) 2006-12-07
US6831085B1 (en) 2004-12-14
EP1707563A3 (de) 2007-06-06
US7105668B1 (en) 2006-09-12
CN1229353C (zh) 2005-11-30
BR0111898A (pt) 2003-05-13
NO324440B1 (no) 2007-10-15
US6630479B1 (en) 2003-10-07
AU5927001A (en) 2002-01-02
HUP0301201A3 (en) 2004-03-29
JP2004501140A (ja) 2004-01-15
AU2001259270B2 (en) 2006-08-24
NZ523233A (en) 2004-10-29
NO20026172L (no) 2003-02-20
IL153554A0 (en) 2003-07-06
CA2413426A1 (en) 2001-12-27
US6562831B1 (en) 2003-05-13
CZ303007B6 (cs) 2012-02-22
EP1707563A2 (de) 2006-10-04
NO20026172D0 (no) 2002-12-20
KR20030047903A (ko) 2003-06-18
SI1296959T1 (sl) 2007-02-28
US7294634B2 (en) 2007-11-13
EP1296959B1 (de) 2006-04-19
KR100847788B1 (ko) 2008-07-23
PT1296959E (pt) 2006-07-31
JP4854906B2 (ja) 2012-01-18
CY1105070T1 (el) 2009-11-04
WO2001098278A1 (en) 2001-12-27
US20040254203A1 (en) 2004-12-16
ES2262649T3 (es) 2006-12-01
IL153554A (en) 2009-09-01
HUP0301201A2 (hu) 2003-12-29
EP1296959A1 (de) 2003-04-02
PL204525B1 (pl) 2010-01-29
MXPA02012627A (es) 2003-09-25
HK1053837A1 (en) 2003-11-07
DE60118921T2 (de) 2006-11-23
PL358412A1 (en) 2004-08-09
CN1437585A (zh) 2003-08-20
HU229078B1 (en) 2013-07-29
CA2413426C (en) 2011-01-04
DK1296959T3 (da) 2006-07-31

Similar Documents

Publication Publication Date Title
DE60118921D1 (de) Verfahren und Zusammensetzungen unter Verwendung von Chinazolinonen
DE60028227D1 (de) Chinazolinone benutzende verfahren und zusammenstellungen
SE9900100D0 (sv) New compounds
WO2004018058A3 (en) Compounds, compositions, and methods
MY140767A (en) Compounds, methods and compositions
MY140169A (en) Compounds, compositions, and methods
WO2004009036A3 (en) Compounds compositions and methods
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004032840A3 (en) Compounds, compositions, and methods
EP1507534A4 (de) Verbindungen, zusammensetzungen und verfahren
WO2005042697A3 (en) Compounds, compositions and methods
WO2004032879A3 (en) Compounds, compositions, and methods
WO2004024086A3 (en) Compounds, compositions and methods
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
WO2005041888A3 (en) Pyrimidin-4-one compounds, compositions and methods
DE502005005474D1 (de) Verwendung von speziellen formylierten chinoliniumderivaten in kombination mit aminosubtituierten pyrimidinderivaten und mindestens einem weiteren primären oder sekundären, aromatischen amin
DE60235589D1 (de) Wortmannin-Analoge und Verfahren zu deren Verwendung
HK1068212A (en) Compounds, methods and compositions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296959

Country of ref document: EP